Exelixis, Inc.

NASDAQ:EXEL

Biotechnology

Healthcare
$68.29 +0.65%

+$0.34 today

Market cap
$17.17B
Beta
0.43
P/E (TTM)
16.3
EPS (TTM)
$3.23
52W Low $33.76High $53.93

Volume 1.82M

Average 2.55M

EXEL Purchases of Investments

Cash used to buy marketable securities and other investments.

Exelixis, Inc.NASDAQ: EXEL

Purchases of Investments · Q2 FY2026 · quarter ended Jul 2026

Purchases of investments declines year over year

Q2 FY2026 purchases of investments of $68.52M (cash outflow) fell 32.5% year over year, behind the -29.1% change in trailing-twelve-month purchases of investments. Sequentially, it fell 75.0% from the prior quarter. Over 3 fiscal years it compounded at -24.2% a year.

Context

  • Purchases of investments amounted to 27.3% of revenue in FY2025, down 15.5 pp from a year earlier.
  • Purchases of investments grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -32.5% toward the trailing-twelve-month pace of -29.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJul 2026
-$68.52M-75.0% QoQ
Last fiscal yearJan 2026
-$632.5M-31.8% YoY
LTMJul 2026
-$686.99M-29.1% YoY
Purchases of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-32.5%——
1 year-31.8%——
3-year CAGR-24.2%——
5-year CAGR——
10-year CAGR——

Purchases of Investments history

USD · from the cash flow

Latest · FY2025
(632.5M) USD
Year-over-year change
+31.8%

Purchases of Investments vs competitors

How EXEL compares with its peers on the latest reported figures

  • EXEL's LTM Jul 2026 purchases of investments of $686.99M is the 2nd largest of the 8 companies compared; the peer median is $224.66M.
  • Its year-over-year change of -29.1% is the 6th highest of 7, against a peer median of +71.5%.
  • Purchases of investments amounts to 28.2% of revenue for EXEL, versus a peer median of 8.8%.
EXEL Competitors Peer median
Purchases of Investments for EXEL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RVMDRevolution Medicines, Inc.LTM Jun 2026$3B +43.1%+43.1%—
EXELExelixis, Inc.LTM Jul 2026$686.99M -29.1%-24.2%28.2%
GMABGenmab A/SLTM Jun 2026$426.07M —-53.2%10.3%
INCYIncyte CorporationLTM Jun 2026$420.12M +177.1%+56.0%7.2%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$224.66M -43.9%-26.6%103.4%
AZNAstraZeneca PLCLTM Sep 2026$213.22M -2.2%+12.9%0.3%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$155.76M +217.1%+74.5%52.0%
HCMHUTCHMED (China) LimitedLTM Jun 2025$0 +100.0%+31.8%0.0%
Peer median (excluding EXEL) $224.66M+71.5%+31.8%8.8%

Competitors are the stored peer set for EXEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Jan 2025
FY2025
Jan 2026
Net Income231.06M182.28M207.77M521.27M782.57M
Depreciation & Amortization13.63M20.88M25.72M28.8M29.06M
Deferred Income Tax46.53M(60.36M)(133.21M)(59.46M)126.24M
Stock-Based Compensation119.82M107.57M106.35M93.84M112.98M
Change in Working Capital(39.01M)(12.8M)(13.97M)(13.45M)(191.2M)
Accounts Receivables(122.32M)66.85M(22.62M)(27.95M)(21.4M)
Inventory(13.21M)(11.68M)(12.98M)5.45M12.23M
Accounts Payables55.09M23.36M50.11M(21.89M)(50.15M)
Other Working Capital41.43M(91.32M)(28.48M)30.93M(131.87M)
Other Non-Cash Items28.78M125.04M140.68M128.98M24.62M
Operating Cash Flow400.8M362.61M333.32M699.97M884.27M
Capital Expenditures(64.23M)(138.46M)(162.97M)(66.19M)(39.93M)
Acquisitions (Net)00000
Purchases of Investments(1.36B)(1.45B)(902.47M)(927.91M)(632.5M)
Sales of Investments1.38B1.06B1.04B877.31M1.02B
Other Investing Activities(10M)(110.75M)(122.5M)(37.75M)(31.5M)
Investing Cash Flow(42.88M)(524.41M)(26.96M)(116.78M)350.44M
Debt Repayment00000
Common Stock Issued023.89M33.45M61.85M49.14M
Common Stock Repurchased00(550.38M)(652.03M)(947.51M)
Dividends Paid00000
Other Financing Activities(14.8M)(23.3M)(29.12M)(38.63M)(71.22M)
Financing Cash Flow(14.8M)586K(546.05M)(628.81M)(969.59M)
Effect of Forex Changes00000
Net Change in Cash343.12M(161.21M)(239.68M)(45.62M)265.11M
Free Cash Flow336.58M224.16M170.36M633.79M844.34M

Exelixis, Inc.

NASDAQ:EXEL

Intrinsic Alpha fair value

Locked

Current Price

$68.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.